Thickened saliva after effective management of drooling with botulinum toxin A

Developmental Medicine and Child Neurology

Volumn 52, Issue 6, 2010, Pages

  Erasmus, Corrie E ^a   Van Hulst, Karen ^a   Van Den Hoogen, Frank Ja ^a   Van Limbeek, Jacques ^b   Roeleveld, Nel ^a   Veerman, Enno Ci ^c   Rotteveel, Jan J ^a   Jongerius, Peter H ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Radboud University Nijmegen Medical Centre ^*  (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; MUCIN; MUCOLYTIC AGENT;

ADOLESCENT; ARTICLE; CEREBRAL PALSY; CHILD; CLINICAL ARTICLE; DYSKINESIA; DYSPHAGIA; FEMALE; FLOW KINETICS; FLOW RATE; GROSS MOTOR FUNCTION CLASSIFICATION SYSTEM; HUMAN; HYPERSALIVATION; INTELLECTUAL IMPAIRMENT; INTELLIGENCE QUOTIENT; MALE; MASTICATION; MEDICAL DECISION MAKING; PARENT; PRIORITY JOURNAL; QUADRIPLEGIA; RISK ASSESSMENT; SALIVA; SALIVA ANALYSIS; SALIVATION; SPASTICITY; SUBMANDIBULAR GLAND;

ADOLESCENT; BOTULINUM TOXIN TYPE A; CEREBRAL PALSY; CHILD; CHILD, PRESCHOOL; DEGLUTITION; EXPECTORANTS; FEMALE; HUMANS; MALE; MASTICATION; MUCINS; PERIPHERAL NERVOUS SYSTEM AGENTS; SALIVA; SIALORRHEA; SUBMANDIBULAR GLAND; TIME FACTORS; VISCOSITY;

EID: 77953925661     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/j.1469-8749.2009.03601.x     Document Type: Article

References (25)

1. Jongerius PH, van den Hoogen FJ, van Limbeek J, Gabreels FJ, van Hulst K, Rotteveel JJ. Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial. Pediatrics 2004, 114:620-7.
2. Tan EK, Lo YL, Seah A, Auchus AP. Recurrent jaw dislocation after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. J Neurol Sci 2001, 190:95-7.
3. Jost WH. Treatment of drooling in Parkinson's disease with botulinum toxin. Mov Disord 1999, 14:1057.
4. Wilken B, Aslami B, Backes H. Successful treatment of drooling in children with neurological disorders with botulinum toxin A or B. Neuropediatrics 2008, 39:200-4.
5. Costa J, Rocha ML, Ferreira J, Evangelista T, Coelho M, de CM. Botulinum toxin type-B improves sialorrhea and quality of life in bulbaronset amyotrophic lateral sclerosis. J Neurol 2008, 255:545-50.
6. Contarino MF, Pompili M, Tittoto P. Botulinum toxin B ultrasound-guided injections for sialorrhea in amyotrophic lateral sclerosis and Parkinson's disease. Parkinsonism Relat Disord 2007, 13:299-303.
7. Stokes JR, Davies GA. Viscoelasticity of human whole saliva collected after acid and mechanical stimulation. Biorheology 2007, 44:141-60.
8. Aguirre A, Mendoza B, Levine MJ, Hatton MN, Douglas WH. In vitro characterization of human salivary lubrication. Arch Oral Biol 1989, 34:675-7.
9. Park MS, Chung JW, Kim YK, Chung SC, Kho HS. Viscosity and wettability of animal mucin solutions and human saliva. Oral Dis 2007, 13:181-6.
10. Zussman E, Yarin AL, Nagler RM. Age- and flow-dependency of salivary viscoelasticity. J Dent Res 2007, 86:281-5.
11. Ellies M, Laskawi R, Rohrbach-Volland S, Arglebe C, Beuche W. Botulinum toxin to reduce saliva flow: selected indications for ultrasound-guided toxin application into salivary glands. Laryngoscope 2002, 112:82-6.
12. Ellies M, Laskawi R, Rohrbach-Volland S, Arglebe C. Up-to-date report of botulinum toxin therapy in patients with drooling caused by different etiologies. J Oral Maxillofac Surg 2003, 61:454-7.
13. Thomas-Stonell N, Greenberg J. Three treatment approaches and clinical factors in the reduction of drooling. Dysphagia 1988, 3:73-8.
14. van der Burg JJ, Jongerius P, van Limbeek J, van Hulst K, Rotteveel J. Drooling in children with cerebral palsy: a qualitative method to evaluate parental perceptions of its impact on daily life, social interaction, and self-esteem. Int J Rehabil Res 2006, 29:179-82.
15. Rapp D. Drool control: long-term follow-up. Dev Med Child Neurol 1980, 22:448-53.
16. Suskind DL, Tilton A. Clinical study of botulinum-A toxin in the treatment of sialorrhea in children with cerebral palsy. Laryngoscope 2002, 112:73-81.
17. Veerman EC, Bank CM, Namavar F, Appelmelk BJ, Bolscher JG, Nieuw Amerongen AV. Sulfated glycans on oral mucin as receptors for Helicobacter pylori. Glycobiology 1997, 7:737-43.
18. Jongerius PH, van Limbeek J, Rotteveel JJ. Assessment of salivary flow rate: biologic variation and measure error. Laryngoscope 2004, 114:1801-4.
19. Rotteveel LJ, Jongerius PH, van Limbeek J, van den Hoogen FJ. Salivation in healthy schoolchildren. Int J Pediatr Otorhinolaryngol 2004, 68:767-74.
20. Dawes C. Circadian rhythms in the flow rate and composition of unstimulated and stimulated human submandibular saliva. J Physiol 1975, 244:535-48.
21. Navazesh M. Methods for collecting saliva. Ann N Y Acad Sci 1993, 694:72-7.
22. Aguirre A, Testa-Weintraub LA, Banderas JA, Haraszthy GG, Reddy MS, Levine MJ. Sialochemistry: a diagnostic tool? Crit Rev Oral Biol Med 1993, 4:343-50.
23. Ballard ST, Spadafora D. Fluid secretion by submucosal glands of the tracheobronchial airways. Respir Physiol Neurobiol 2007, 159:271-7.
24. Perez-Vilar J, Boucher RC. Reevaluating gel-forming mucins' roles in cystic fibrosis lung disease. Free Radic Biol Med 2004, 37:1564-77.
25. Rubin BK. Mucus structure and properties in cystic fibrosis. Paediatr Respir Rev 2007, 8:4-7.